News about "Eli Lilly and Company "

Eli Lilly Appoints New Executives, Expands Senior Leadership Roles to Drive Next Phase of Growth

Eli Lilly has appointed Carole Ho and Adrienne Brown to lead the company’s expansion in neuroscience and immunology, while also broadening the responsibilities of Daniel Skovronsky and Jacob Van Naarden to further strengthen its leadership team.

Eli Lilly And Company | 07/11/2025 | By Dineshwori

Lilly to Establish USD 5 Billion API Manufacturing Facility in Virginia

The new site in Virginia marks the first of four new US manufacturing sites that Lilly plans to announce this year.

Eli Lilly And Company | 17/09/2025 | By Dineshwori

Alchemab Launches First-in-Human Trial of ATLX-1282, Secures 32 Million USD Financing Boost

Alchemab Therapeutics, a biopharmaceutical company that develops naturally occurring therapeutic antibodies from resilient individuals, has announced the initiation of its first-in-human phase 1 study of ATLX-1282.

Eli Lilly And Company | 10/09/2025 | By Darshana |  164

Lilly Completes Acquisition of Verve Therapeutics

Eli Lilly and Company has completed its acquisition of Verve Therapeutics, a Boston-based clinical-stage firm developing genetic medicines for cardiovascular disease.

Eli Lilly And Company | 26/07/2025 | By Mrinmoy Dey |  232

Juvena Therapeutics & Eli Lilly and Company ink research collaboration focused on muscle health

As part of the collaboration, Juvena will leverage JuvNET, the world’s first, fully integrated, AI-enabled screening platform for mapping the therapeutic potential of stem cell-secreted proteins, developed by Juvena.

Eli Lilly And Company | 15/06/2025 | By Darshana |  127

Nimbus Therapeutics Hits Preclinical Research Milestone with Lilly

Throughout their collaboration, Nimbus has leveraged its computational approaches and structure-based drug design capabilities to help overcome these historical obstacles.

Eli Lilly And Company | 26/02/2025 | By Aishwarya |  250

Eli Lilly's Omvoh Shows Long-Term Efficacy in Crohn's Disease: VIVID-2 Study Results Announced

Omvoh works to reduce inflammation within the gastrointestinal tract by targeting a specific protein, interleukin-23p19 (IL-23p19), which is a key contributor to intestinal inflammation.

Eli Lilly And Company | 07/02/2025 | By Abha |  293

Lilly and EVA Pharma Secure Approval to Distribute Locally Manufactured Insulin in Egypt

Under this agreement, Lilly has been supplying its active pharmaceutical ingredient (API) for insulin to EVA Pharma at a significantly reduced price and providing pro-bono technology transfer to enable EVA Pharma to formulate, fill and finish insulin vials and cartridges.

Eli Lilly And Company | 18/12/2024 | By Aishwarya |  566

Lilly to Invest USD 3 Billion to Expand its Manufacturing Facility in Wisconsin

Lilly expects to add 750 highly skilled jobs to the current 100-plus workforce at this location.

Eli Lilly And Company | 06/12/2024 | By Aishwarya |  163

Lilly Gets FDA Approval for EBGLYSS for Atopic Dermatitis

Eli Lilly and Company has announced that the US Food and Drug Administration (FDA) approved EBGLYSS (lebrikizumab-lbkz), a targeted IL-13 inhibitor, for the treatment of adults and children 12 years of age and older who weigh at least 88 pounds (40 kg) with moderate-to-severe atopic dermatitis.

Eli Lilly And Company | 17/09/2024 | By Aishwarya |  534